**Electronic supplementary material 1: Literature search strategy**

|  |  |
| --- | --- |
| Database | Search strategy |
| **Ovid MEDLINE(R)** | 1 exp \*"Bipolar and Related Disorders"/, 2 exp \*Bipolar Disorder/, 3 bipolar.ab,ti.,4 bipolar disorder.ab,ti., 5 psychosis.ab,ti., 6 exp \*Psychotic Disorders/, 7 exp \*Affective Disorders Psychotic/, 8 psychotic.ab,ti., 9 psychotic disorder.ab,ti., 10 exp \*Schizophrenia/, 11 exp \*Schizophrenia Disorganized/, 12 exp \*Schizophrenia, Paranoid/, 13 exp \*Schizophrenia, Catatonic/, 14 Schizophrenia.ab,ti., 15 severe mental illness.ab,ti., 16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15, 17 addiction.ab,ti., 18 exp \*Alcoholism/, 19 alcohol abuse.ab,ti., 20 exp \*Substance-Related Disorders/, 21 exp \*Alcohol Drinking/, 22 alcohol addict.ab,ti., 23 alcohol dependence.ab,ti., 24 exp \*Alcohol-Related Disorders/, 25 alcohol misuse.ab,ti., 26 alcohol related disorder.ab,ti., 27 alcohol disorder.ab,ti., 28 alcoholic.ab,ti., 29 exp \*Alcoholics/, 30 alcoholism.ab,ti., 31 exp \*Binge Drinking/, 32 exp \*Alcoholic Intoxication/, 33 binge drinking.ab,ti., 34 exp \*Prescription Drug Diversion/, 35 controlled drug diversion.ab,ti., 36 drug abuse.ab,ti., 37 drug addict.ab,ti., 38 drug dependence.ab,ti., 39 exp \*Drug Misuse/, 40 exp \*Prescription Drug Misuse/, 41 exp \*Substance Abuse, Intravenous/, 42 drug misuse.ab,ti., 43 exp \*Illicit Drugs/, 44 drug of abuse.ab,ti., 45 drugs of dependence.ab,ti., 46 hazardous drinking.ab,ti., 47 Illegal drug.ab,ti., 48 exp \*Alcohol-Related Disorders/, 49 Illicit drug.ab,ti., 50 exp \*Opioid-Related Disorders/, 51 opioid dependence.ab,ti., 52 exp \*Substance Withdrawal Syndrome/, 53 opioid withdrawal.ab,ti., 54 drug overdose.ab,ti., 55 exp \*Drug Overdose/, 56 drug overuse.ab,ti., 57 polysubstance.ab,ti., 58 Prescription drug abuse.ab,ti., 59 prescription drug diversion.ab,ti., 60 problem substance.ab,ti., 61 severe opioid intoxication.ab,ti., 62 substance abuse.ab,ti., 63 substance abuse, intravenous.ab,ti., 64 exp \*Substance Abuse, Oral/, 65 substance abuse, oral.ab,ti., 66 substance addict.ab,ti., 67 substance dependence.ab,ti., 68 exp \*Psychoses, Substance-Induced/, 69 Substance induced.ab,ti., 70 substance related disorder.ab,ti., 71 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70, 72 16 and 71, 73 limit 72 to (english language and yr="2010 -Current") |
| **APA PsychInfo + EMBASE** | 1 bipolar disorder.ab,ti., 2 bipolar.ab,ti.3 psychosis.ab,ti., 4 (bipolar and related disorder).ab,ti., 5 psychotic disorder.ab,ti., 6 psychotic affective disorder.ab,ti., 7 psychotic.ab,ti., 8 Schizophrenia.ab,ti., 9 disorganized Schizophrenia.ab,ti., 10 paranoid Schizophrenia.ab,ti., 11 catatonic Schizophrenia.ab,ti., 12 severe mental illness.ab,ti., 13 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12, 14 addiction.ab,ti., 15 alcoholism.ab,ti., 16 alcohol abuse.ab,ti., 17 substance related disorder.ab,ti., 18 alcohol drinking.ab,ti., 19 alcohol addict.ab,ti., 20 alcohol dependence.ab,ti., 21 alcohol related disorder.ab,ti., 22 alcohol misuse.ab,ti., 23 alcohol disorder.ab,ti., 24 alcoholic.ab,ti., 25 binge drinking.ab,ti., 26 alcoholic intoxication.ab,ti., 27 prescription drug diversion.ab,ti., 28 controlled drug diversion.ab,ti., 29 drug abuse.ab,ti., 30 drug addict.ab,ti., 31 drug dependence.ab,ti., 32 drug misuse.ab,ti., 33 prescription drug misuse.ab,ti., 34 substance abuse, intravenous.ab,ti., 35 Illicit drug.ab,ti., 36 Illegal drug.ab,ti., 37 drug of abuse.ab,ti., 38 drug of dependence.ab,ti., 39 hazardous drinking.ab,ti., 40 opioid -related disorders.ab,ti., 41 opioid dependence.ab,ti., 42 substance withdrawal syndrome.ab,ti., 43 opioid withdrawal.ab,ti., 44 drug overdose.ab,ti., 45 drug overuse.ab,ti., 46 polysubstance.ab,ti., 47 Prescription drug abuse.ab,ti., 48 problem substance.ab,ti., 49 severe opioid intoxication.ab,ti., 50 substance abuse.ab,ti., 51 substance abuse, oral.ab,ti., 52 substance addict.ab,ti., 53 substance dependence.ab,ti., 54 substance induced psychosis.ab,ti., 55 substance induced.ab,ti., 56 substance related disorder.ab,ti., 57 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56, 58 13 and 57, 59 limit 58 to english language, 60 limit 59 to yr="2010 -Current", 61 screening.ab,ti., 62 diagnosis.ab,ti., 63 dual diagnosis.ab,ti., 64 disease management.ab,ti., 65 medication therapy management.ab,ti., 66 medical practice management.ab,ti., 67 management.ab,ti., 68 therapeutics.ab,ti., 69 treatment.ab,ti., 70 referral.ab,ti., 71 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70, 72 13 and 57 and 71, 73 limit 72 to english language, 74 limit 73 to yr="2010 -Current" |

**Electronic supplementary material 2: PRISMA checklist\* for the present review**

|  |  |  |  |
| --- | --- | --- | --- |
| **Section/topic**  | **#** | **Checklist item**  | **Reported on section**  |
| **TITLE**  |  |
| Title  | 1 | Identify the report as a systematic review, meta-analysis, or both.  | Title page |
| **ABSTRACT**  |  |
| Structured summary  | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.  | Abstract page |
| **INTRODUCTION**  |  |
| Rationale  | 3 | Describe the rationale for the review in the context of what is already known.  | Background  |
| Objectives  | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).  | Background  |
| **METHODS**  |  |
| Protocol and registration  | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.  | Title page and Methodology |
| Eligibility criteria  | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.  | Methodology |
| Information sources  | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.  | Methodology |
| Search  | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  | Supplement 1 |
| Study selection  | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).  | Methodology |
| Data collection process  | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.  | Methodology |
| Data items  | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.  | Methodology |
| Risk of bias in individual studies  | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.  | Methodology |
| Summary measures  | 13 | State the principal summary measures (e.g., risk ratio, difference in means).  | NA |
| Synthesis of results  | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis.  | Methodology |

|  |  |  |  |
| --- | --- | --- | --- |
| **Section/topic**  | **#** | **Checklist item**  | **Reported on page #**  |
| Risk of bias across studies  | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).  | Methodology |
| Additional analyses  | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.  | NA |
| **RESULTS**  |  |
| Study selection  | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.  | Results  |
| Study characteristics  | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.  | Results |
| Risk of bias within studies  | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  | Results |
| Results of individual studies  | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  | NA |
| Synthesis of results  | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency.  | Results |
| Risk of bias across studies  | 22 | Present results of any assessment of risk of bias across studies (see Item 15).  | NA |
| Additional analysis  | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  | NA |
| **DISCUSSION**  |  |
| Summary of evidence  | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).  | Discussion  |
| Limitations  | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).  | Discussion |
| Conclusions  | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research.  | Discussion |
| **FUNDING**  |  |
| Funding  | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.  | NA |

**\*Checklist adapted from** Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097.

**Electronic supplementary material 3: AGREE II score sheet**

| **Domain** | **Item** | **AGREE II Rating** |
| --- | --- | --- |
| **1** *Strongly Disagree* | **2** | **3** | **4** | **5** | **6** | **7** *Strongly Agree* |
| Scope and purpose | 1. The overall objective(s) of the guideline is (are) specifically described.
 |  |  |  |  |  |  |  |
| 1. The health question(s) covered by the guideline is (are) specifically described.
 |  |  |  |  |  |  |  |
| 1. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described.
 |  |  |  |  |  |  |  |
| Stakeholder involvement | 1. The guideline development group includes individuals from all the relevant professional groups.
 |  |  |  |  |  |  |  |
| 1. The views and preferences of the target population (patients, public, etc.) have been sought.
 |  |  |  |  |  |  |  |
| 1. The target users of the guideline are clearly defined.
 |  |  |  |  |  |  |  |
| Rigor of development | 1. Systematic methods were used to search for evidence.
 |  |  |  |  |  |  |  |
| 1. The criteria for selecting the evidence are clearly described.
 |  |  |  |  |  |  |  |
| 1. The strengths and limitations of the body of evidence are clearly described.
 |  |  |  |  |  |  |  |
| 1. The methods for formulating the recommendations are clearly described.
 |  |  |  |  |  |  |  |
| 1. The health benefits, side effects and risks have been considered in formulating the recommendations.
 |  |  |  |  |  |  |  |
| 1. There is an explicit link between the recommendations and the supporting evidence.
 |  |  |  |  |  |  |  |
| 1. The guideline has been externally reviewed by experts prior to its publication.
 |  |  |  |  |  |  |  |
| 1. A procedure for updating the guideline is provided.
 |  |  |  |  |  |  |  |
| Clarity of presentation | 1. The recommendations are specific and unambiguous.
 |  |  |  |  |  |  |  |
| 1. The different options for management of the condition or health issue are clearly presented.
 |  |  |  |  |  |  |  |
| 1. Key recommendations are easily identifiable.
 |  |  |  |  |  |  |  |
| Applicability | 1. The guideline describes facilitators and barriers to its application.
 |  |  |  |  |  |  |  |
| 1. The guideline provides advice and/or tools on how the recommendations can be put into practice.
 |  |  |  |  |  |  |  |
| 1. The potential resource implications of applying the recommendations have been considered.
 |  |  |  |  |  |  |  |
| 1. The guideline presents monitoring and/ or auditing criteria.
 |  |  |  |  |  |  |  |
| Editorial independence | 1. The views of the funding body have not influenced the content of the guideline.
 |  |  |  |  |  |  |  |
| 1. Competing interests of guideline development group members have been recorded and addressed.
 |  |  |  |  |  |  |  |
| Overall Guideline Assessment | 1. Rate the overall quality of this guideline.
 | **1** *Lowest possible quality* | **2** | **3** | **4** | **5** | **6** | **7** *Highest possible quality* |
| Overall Guideline Assessment | 1. I would recommend this guideline for use.
 | *Yes* | *Yes, with modifications* | *No* |